Study title: K.E.E.P.E.R. (KEPPRA(R) EPILEPSY EVALUATION OF PATIENT TIME TO RESPONSE). A PHASE IV, OPEN-LABEL, MULTI-CENTER, COMMUNITY-BASED TRIAL STUDYING THE SAFETY AND EFFICACY OF LEVETIRACETAM AS ADD-ON THERAPY IN ADULT PATIENTS WITH TREATMENT-RESISTANT, PARTIAL-ONSET EPILEPSY.
Type of medicine: Centrally authorised medicines | |||||
Therapeutic area: Nervous System Diseases | |||||
Brands: Please see report, Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: levetiracetam | |||||
ATC code: N03AX14 | |||||
Document link: N01030 - Levetiracetam - RRCE02E1301.pdf | |||||
Document date: 2011-11-28 | |||||
Study number: RRCE02E1301 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |